Class Action Settlement Announced for QVAR® and QVAR RediHaler® Inhalers
A class action settlement has been reached involving Teva Pharmaceutical Industries Ltd. and related entities over alleged anti-competitive practices regarding QVAR® and QVAR RediHaler® inhalers. The settlement includes $35 million to be distributed to affected consumers and third-party payors who purchased or reimbursed for the inhalers between January 1, 2015, and July 31, 2025. Teva denies wrongdoing, and the settlement does not imply any safety issues with the products.
Tickers: $TEVA
Topics: antitrust class action lawsuit pharmaceutical industry QVAR inhalers settlement Teva Pharmaceuticals